Intravenous Use of Metoclopramide and Sustained Hypotension: A Case Report

Document Type : Case Report

Authors

1 National Medicines and Food Administration, Asmara, Eritrea.

2 Tesessney Hospital, Tesseney

Abstract

Introduction:
Transient hypotension has been commonly associated with metoclopramide hydrochloride, particularly with intravenous use. However, the risk of sustained hypotension that lasts for hours has not been previously associated with metoclopramide, except for one published case report. This case report is aimed at documenting the second case of unusual and serious sustained hypotension that lasted for more than six hours following rapid intravenous use of metoclopramide prescribed for the prevention of cesarean section delivery related intra/postoperative nausea and vomiting.
Case Report:
A 33-year-old gravida III and para II woman was admitted to a hospital for an elective cesarean section delivery with normal baseline blood pressure. Following metoclopramide 10 mg intravenous push administration, over 5-10 seconds, the mother encountered sustained hypotension (60/40 mmHg) that lasted for 120 minutes. After resuscitation, her blood pressure raised to 105/60 mmHg. However, after spinal anesthesia with bupivacaine hydrochloride, her diastolic arterial blood pressure dropped back again to 40 mmHg which persisted for about six hours post-operation. Upon investigation, the sustained hypotension was found to be probably related to inappropriate and rapid administration of intravenous bolus dose of metoclopramide hydrochloride that could have been prevented since it should be administered slowly over at least three minutes.
Conclusion:
The risk of metoclopramide-induced hypotension should not be underestimated as it sometimes might be much severe than the risk of nausea and vomiting that warrants immediate attention from healthcare professionals and program managers.

Keywords

References

  1. Medicines and Healthcare Products Regulatory Agency. Summary of product characteristics of metoclopramide hydrochloride 5mg/ml injection. Hameln Pharma Ltd. Updated 22/07/2020. Available from: https: //www. medicines. org.uk/ emc/ product/6283/smpc. Accessed on January 3, 2021.
  2. United States Food and Drug Administration. Prescribing information of metoclopramide hydrochloride 5mg/ml injection. Available from: https://www. accessdata. fda.gov/drugsatfda_docs/label/ 2010/017862s063lbl.pdf. Accessed January 3, 2021.
  3. Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images. 2012; 3(5):1–10. URL: http: //www. ijcasereportsandimages. com/ archive/ 2012/005-2012-ijcri/001-05-2012-rumore/ ijcri-00105201211-rumore-full-text.php#ref44
  4. New Zealand data sheet of Metoclopramide‐ Baxter 5mg/mL solution for injection. Baxter Healthcare Ltd. Updated on November 2019. Available from: https: // www. medsafe. govt.nz/ Profs/Datasheet/m/MetoclopramideClarisinj.pd f. Accessed January 3, 2021.
  5. Nguyen TT, Gimbar RMP. Sustained hypotension following intravenous metoclo pramide. Ann Pharmacother. 2013 Nov; 47 (11):1577-80.doi:10.1177/1060028013503789. URL: https://journals. sagepub. com/doi/ pdf/ 10.1177/1060028013503789
  6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239–45.
  7. Cyna AM, Andrew M, Emmett RS, Middleton P, Simmons SW. Techniques for preventing hypotension during spinal anesthesia for cesarean section. Cochrane Database Syst Rev 2006; 4:CD002251.
  8. Leykin Y, Rubulotta F. Prophylactic continuous intravenous ephedrine infusion for elective Cesarean section under spinal anaesthesia. Eur J Anaesthesiol. 2003; 20: 257–8.
  9. Ngan Kee WD, Khaw KS, Ng FF. Comparison of phenylephrine infusion regimens for maintaining maternal blood pressure during spinal anaesthesia for Caesarean section. Br J Anaesth. 2004; 92: 469–74.
  10. Benkirane R, Soulaymani R, Khattabi A, Benabdallah G, Alj L, Sefiani H, et al. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Saf. 2014; 38(4).
  11. Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther. 1988; 244(3): 830–7. URL: https:// jpet. aspetjournals. org/ content/244/3/830
  12. Watts SW, Davis RP. 5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther. 2011; 29(1): 54-67. doi:10.1111/j.1755-5922. 2010. 00173.x.
  13. Bagdy G, Calogero AE, Murphy DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitaryadrenocortical axis in conscious rats. Endocrinology. 1989 Nov; 125(5):2664-9.
  14. Ferreira HS, de Castro e Silva E, Cointeiro C, Oliveira E, Faustino TN, Fregoneze JB. Role of central 5-HT3 receptors in the control of blood pressure in stressed and non-stressed rats. Brain Res. 2004 Nov 26;1028(1):48-58. doi: 10. 1016/ j.brainres.2004.08.063.
  15. Morgan PJ, Halpern SH, Tarshis J. The effects of an increase of central blood volume before spinal anesthesia for cesarean delivery: a qualitative systematic review. Anesth Analg. 2001;92:997–1005.
Journal of Patient Safety & Quality Improvement
Volume 9, Issue 1
January 2021
Pages 65-68

Files

Share

How to cite

Statistics